Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 20 12 2021
revised: 17 01 2022
accepted: 19 01 2022
entrez: 27 2 2022
pubmed: 28 2 2022
medline: 8 3 2022
Statut: ppublish

Résumé

Polymorphous adenocarcinoma (PAC) is a low-grade salivary gland malignancy in contrast to variants with papillary (PAP) or cribriform (CASG) architecture and confers the second most common malignancy of minor salivary glands. Our study aimed to identify prognostic factors and to evaluate histomorphological and molecular diagnostic criteria of PACs. A series of 155 PACs, including 10 PAPs and 12 CASGs from the population-based Cancer Registry of North Rhine-Westphalia (LKR-NRW) and the Hamburg Salivary Gland Reference Centre (HRC) were analyzed. One fifth of the tumors were located in the major salivary glands and PACS/CASGS invariably lacked p40 expression. Fifty-two percent of PACs showed a PRKD1 E710D mutation. Ordinary PACs had a disease-specific 10-year survival probability of 97% compared to 90% when combining PAPs and CASGs. T-stage at diagnosis was a prognostic factor with 98% for stages T1/T2 versus 75% for T3/T4. Diagnostic algorithms for the PAC/CASG spectrum of tumors need to be improved and should include molecular markers.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Polymorphous adenocarcinoma (PAC) is a low-grade salivary gland malignancy in contrast to variants with papillary (PAP) or cribriform (CASG) architecture and confers the second most common malignancy of minor salivary glands. Our study aimed to identify prognostic factors and to evaluate histomorphological and molecular diagnostic criteria of PACs.
PATIENTS AND METHODS METHODS
A series of 155 PACs, including 10 PAPs and 12 CASGs from the population-based Cancer Registry of North Rhine-Westphalia (LKR-NRW) and the Hamburg Salivary Gland Reference Centre (HRC) were analyzed.
RESULTS RESULTS
One fifth of the tumors were located in the major salivary glands and PACS/CASGS invariably lacked p40 expression. Fifty-two percent of PACs showed a PRKD1 E710D mutation. Ordinary PACs had a disease-specific 10-year survival probability of 97% compared to 90% when combining PAPs and CASGs. T-stage at diagnosis was a prognostic factor with 98% for stages T1/T2 versus 75% for T3/T4.
CONCLUSION CONCLUSIONS
Diagnostic algorithms for the PAC/CASG spectrum of tumors need to be improved and should include molecular markers.

Identifiants

pubmed: 35220239
pii: 42/3/1455
doi: 10.21873/anticanres.15616
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1455-1463

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Stella Clausen (S)

Department of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.

Markus Falk (M)

Institute for Hematopathology, Hamburg, Germany; falk@hp-hamburg.de.

Florian Oesterling (F)

Cancer Registry North Rhine-Westphalia, Bochum, Germany.

André Fehr (A)

Sahlgrenska Center for Cancer Research, Department of Pathology, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

Andreas Stang (A)

Cancer Registry North Rhine-Westphalia, Bochum, Germany.
Institute of Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.

Werner Boecker (W)

Gerhard Seifert Reference-Center - Hansepathnet, Hamburg, Germany.

Stefan Gesk (S)

Institute for Tumor Genetics North, Kiel, Germany.

Stefanie Schatz (S)

Institute for Hematopathology, Hamburg, Germany.

Göran Stenman (G)

Sahlgrenska Center for Cancer Research, Department of Pathology, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

Katharina Tiemann (K)

Institute for Hematopathology, Hamburg, Germany.

Thomas Loening (T)

Gerhard Seifert Reference-Center - Hansepathnet, Hamburg, Germany.

Reinhard E Friedrich (RE)

Department of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH